Modified outpatient dexamethazone, cytarabine and cisplatin regimen may lead to high response rates and low toxicity in Lymphoma

Simple item page
dc.contributor.authorÖzet, Ahmet
dc.contributor.authorAtaergin, Selmin
dc.contributor.authorArpacı, Fikret
dc.contributor.authorKuzhan, Okan
dc.contributor.authorKömürcü, Şeref
dc.contributor.authorÖztürk, Bekir
dc.contributor.authorÖztürk, Mustafa
dc.contributor.buuauthorKanat, Özkan
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Onkoloji Anabilim Dalı.tr_TR
dc.contributor.scopusid55881548500tr_TR
dc.date.accessioned2022-03-15T10:37:21Z
dc.date.available2022-03-15T10:37:21Z
dc.date.issued2010
dc.description.abstractObjective: Our purpose was to investigate the efficacy of and establish a toxicity profile for a modified regimen of dexamethasone, cytarabine and cisplatin (DHAP) for lymphoma outpatients. Subjects and Methods: Fifty-one lymphoma patients, 26 with Hodgkin's disease and 25 with non-Hodgkin's lymphoma, were included. The patients' median age was 32 years (range: 17-61). Twenty had progressive/refractory disease and 31 relapsed disease. Twenty-five were in clinical stage I/II and 26 in clinical stage III/IV before the initiation of salvage chemotherapy. DHAP consisted of dexamethasone (40 mg i.v. on days 1-4), cytarabine (2 g/m(2) i.v. as 3-hour infusion on days 2 in the evening and 3 in the morning) and cisplatin (35 mg/m(2) as 2-hour infusion on days 1-3) were administered every 21 days. A total of 154 cycles of modified DHAP were administered, with a median of 3 cycles per patient (range: 2-4). Results: The main toxicity was myelosuppression. WHO grade III-IV neutropenia and grade III-IV thrombocytopenia were observed in 27 (52.9%) and 21 (41%) patients, respectively. The overall response rate (85% for Hodgkin's disease and 95% for non-Hodgkin's lymphoma) was 88.3% (39.2% complete response and 49.1% partial response). Conclusion: The results showed that this outpatient schedule of DHAP was well tolerated and an effective salvage regimen.en_US
dc.identifier.citationKanat, Ö. vd. (2010). "Modified outpatient dexamethazone, cytarabine and cisplatin regimen may lead to high response rates and low toxicity in Lymphoma". Medical Principles and Practice, 19(5), 344-347.en_US
dc.identifier.endpage347tr_TR
dc.identifier.issn1011-7571
dc.identifier.issn1423-0151
dc.identifier.issue5tr_TR
dc.identifier.pubmed20639655tr_TR
dc.identifier.scopus2-s2.0-77954813631tr_TR
dc.identifier.startpage344tr_TR
dc.identifier.urihttps://doi.org/10.1159/000316370
dc.identifier.urihttps://pubmed.ncbi.nlm.nih.gov/20639655/
dc.identifier.urihttp://hdl.handle.net/11452/25041
dc.identifier.volume19tr_TR
dc.identifier.wos000280519300004tr_TR
dc.indexed.pubmedPubmeden_US
dc.indexed.scopusScopusen_US
dc.indexed.wosSCIEen_US
dc.language.isoenen_US
dc.publisherKargeren_US
dc.relation.collaborationYurt içitr_TR
dc.relation.journalMedical Principles and Practiceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectDexamethasone, cytarabine and cisplatinen_US
dc.subjectNon-Hodgkin's lymphomaen_US
dc.subjectHodgkin's diseaseen_US
dc.subjectSalvage chemotherapyen_US
dc.subjectEffective salvage therapyen_US
dc.subjectDiseaseen_US
dc.subjectTransplantationen_US
dc.subjectCytoreductionen_US
dc.subjectChemotherapyen_US
dc.subjectIfosfamideen_US
dc.subjectEtoposideen_US
dc.subjectESHAPen_US
dc.subjectDHAPen_US
dc.subjectGeneral & internal medicineen_US
dc.subject.emtreeBleomycinen_US
dc.subject.emtreeCisplatinen_US
dc.subject.emtreeCyclophosphamideen_US
dc.subject.emtreeCytarabineen_US
dc.subject.emtreeDacarbazineen_US
dc.subject.emtreeDexamethasoneen_US
dc.subject.emtreeDoxorubicinen_US
dc.subject.emtreeFolinic aciden_US
dc.subject.emtreeMethotrexateen_US
dc.subject.emtreePrednisoneen_US
dc.subject.emtreeVinblastineen_US
dc.subject.emtreeVincristineen_US
dc.subject.emtreeAntineoplastic agenten_US
dc.subject.emtreeCisplatinen_US
dc.subject.emtreeCytarabineen_US
dc.subject.emtreeDexamethasoneen_US
dc.subject.emtreeAdolescenten_US
dc.subject.emtreeAdulten_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeBone marrow suppressionen_US
dc.subject.emtreeCancer combination chemotherapyen_US
dc.subject.emtreeCancer stagingen_US
dc.subject.emtreeDrug efficacyen_US
dc.subject.emtreeHodgkin diseaseen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeLymphomaen_US
dc.subject.emtreeMajor clinical studyen_US
dc.subject.emtreeMultiple cycle treatmenten_US
dc.subject.emtreeNephrotoxicityen_US
dc.subject.emtreeNeurotoxicityen_US
dc.subject.emtreeNeutropeniaen_US
dc.subject.emtreeNonhodgkin lymphomaen_US
dc.subject.emtreeOutpatient careen_US
dc.subject.emtreeThrombocytopeniaen_US
dc.subject.emtreeTreatment responseen_US
dc.subject.emtreeClinical trialen_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeLymphoma, non-hodgkinen_US
dc.subject.emtreeMaleen_US
dc.subject.emtreeMiddle ageden_US
dc.subject.emtreeOutpatienten_US
dc.subject.emtreePhase 2 clinical trialen_US
dc.subject.emtreeYoung adulten_US
dc.subject.meshAdolescenten_US
dc.subject.meshAdulten_US
dc.subject.meshAntineoplastic combined chemotherapy protocolsen_US
dc.subject.meshCisplatinen_US
dc.subject.meshCytarabineen_US
dc.subject.meshDexamethasoneen_US
dc.subject.meshFemaleen_US
dc.subject.meshHodgkin diseaseen_US
dc.subject.meshHumansen_US
dc.subject.meshLymphoma, non-hodgkinen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle ageden_US
dc.subject.meshOutpatientsen_US
dc.subject.meshYoung adulten_US
dc.subject.scopusLarge Cell Lymphoma; Burkitt Lymphoma; Rituximaben_US
dc.subject.wosMedicine, general & internalen_US
dc.titleModified outpatient dexamethazone, cytarabine and cisplatin regimen may lead to high response rates and low toxicity in Lymphomaen_US
dc.typeArticle
dc.wos.quartileQ3en_US

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Kanat_vd_2010.pdf
Size:
104.84 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Web of Science
PubMed
Scopus